Emmaus Life Sciences Q3 2023 net income $0.1M vs loss of $0.4M year ago

Emmaus Life Sciences, Inc.

2023-Q3 EPS reported -$0.09 revenue$22,530,000

Q3 net revenues $5.0M, up from $4.9M in Q3 2022; nine-month revenues $22.5M vs $12.5M.
Q3 income from operations $0.02M, compared to operating loss of $0.7M in Q3 2022.
Net loss for nine months 2023 was $4.9M ($0.09/share), improved from $10.8M ($0.22/share) in 2022.
Inventory shortage of Endari caused lower Q3 sales; remedied, expects recovery in Q4.
Cash and cash equivalents $1.5M at Sep 30, 2023, down from $2.0M at Dec 31, 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Emmaus Life Sciences, Inc. reported the three months ended September 30, 2023 results: net income net income of $0.1 million, EPS $0.00 per share based on approximately 53.6 million weighted average basic common shares and a net loss of $0.01 per sha.

Period: the three months ended September 30, 2023
Net income: net income of $0.1 million
EPS: $0.00 per share based on approximately 53.6 million weighted average basic common shares and a net loss of $0.01 per sha
Result: reported results

Exact text from the filing

For the quarter, the company realized net income of $0.1 million, or $0.00 per share based on approximately 53.6 million weighted average basic common shares and a net loss of $0.01 per share based on approximately 138.4 million weighted average diluted common shares.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Emmaus Life Sciences, Inc. reported the three and nine months ended September 30, 2023 results: revenue $5.0 million and $22.5 million, respectively.

Period: the three and nine months ended September 30, 2023
Revenue: $5.0 million and $22.5 million, respectively
Result: reported results

Exact text from the filing

Net revenues for the three months and nine months ended September 30, 2023 were $5.0 million and $22.5 million, respectively, compared to $4.9 million and $12.5 million, respectively, for same periods in 2022.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Emmaus Life Sciences, Inc. reported the nine months ended September 30, 2023 results: net income net loss of $4.9 million, EPS $0.09 per share, based on approximately 52.4 million weighted average basic and diluted common shares.

Period: the nine months ended September 30, 2023
Net income: net loss of $4.9 million
EPS: $0.09 per share, based on approximately 52.4 million weighted average basic and diluted common shares
Result: reported results

Exact text from the filing

For the nine months ended September 30, 2023, the company reported a net loss of $4.9 million, or $0.09 per share, based on approximately 52.4 million weighted average basic and diluted common shares.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Emmaus Life Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-086486

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.